Figure 2
THA decreased Aβ production by inhibiting BACE1 translation in CHO-APP/BACE1 cells and astrocytes. (A) CHO-APP/BACE1 cells were cultured with different concentrations of THA (20, 10, 1, or 0 μg/mL) for 24 h, and sAPPβ levels were detected by ELISA assays in the supernatant. (B) A FRET-based BACE1 enzyme reaction system was directly incubated with different concentrations of THA (20, 10, 1, or 0 μg/mL), and an in vitro BACE1 activity was then evaluated. (TDC: 2,2′,4′-trihydroxychalcone, BACE1 non-competitive inhibitor45). (C, D) Cells were cultured with different concentrations of THA (20, 10, 1, 0 or μg/mL) for 24 h, and levels of eIF2α and PERK was detected by Western blot assays in the CHO-APP/BACE1 cells (C) and astrocytes (D). (E) An RT-PCR assay was used to test the effect of THA on BACE1 transcription. (F) Densitometry analysis of Figure (C). (G) Densitometry analysis of Figure (D). GAPDH was used as a loading control in the Western blot assays. The results were obtained from three independent experiments. Values are the mean±SEM, one-way ANOVA, Bonferroni's multiple comparison test. n=3. **P<0.01 compared with the control group, control group: 0 μg/mL THA treatment group.
